CEO and CoFounder
“Improving the world…
One molecule at a time.”
Russ leads Team Amprion with a vision to revolutionize the diagnosis for Alzheimer’s, Parkinson’s and other neurodegenerative diseases, paving a breakthrough pathway to reinvent drug development and discovery for these elusive, incurable diseases. Russ also brings a unique hands-on expertise in guiding novel diagnostic technologies through the FDA regulatory process.
Prion to co-founding Amprion, Russ worked successfully as senior scientist and research physician in a variety of academic settings before transitioning to an executive management role focusing on financial and operations of emerging biotech companies in diagnostics, therapeutics, and consumer healthcare fields.
Between 1997 and 2003, Russ managed global projects in operations, marketing, and finance for a number of Fortune 100 companies, including Royal Dutch Shell, Enron, ABB, Sprint Nextel, AT&T Wireless, Johnson & Johnson, Merck, Compaq/HP, King Pharmaceuticals, and JPMorgan Chase. Since 2003, Russ has been a serial entrepreneur and active investor in life sciences projects involving protein diagnostics, imaging technology, image analysis, machine learning, drug development, and medical devices.
Having served on the faculty of Baylor College of Medicine in Houston and The Fox Chase Cancer Center in Philadelphia, Russ currently serves on the Board of Directors for Amprion, as well as for Skincential Sciences, Ambra Biosciences, and FP Complete. Russ is an active life sciences venture partner and advisor to several early stage funds in Silicon Valley and overseas.
“We have great science, great people. And we’re trying to solve really difficult but important problems.”